Importantly, RT-induced CTL priming supported by CD86 blockade allowed for reversal of the Treg/CTL ratio, whereas PD-1 blockade likely improved CTL quality, thereby enhancing tumor control. This evidence concerns the gene CD86 and neoplasm.